Ligand Pharma (LGND) Tops Q3 EPS by 40c; offers guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 --0%
Revenue Growth %: -32.2%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
(Updated - November 8, 2023 5:30 PM EST)
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.02, $0.40 better than the analyst estimate of $0.62. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $27.22 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $5.25-$5.40, versus the consensus of $5.04. Ligand Pharma sees FY2023 revenue of $126-129 million, versus the consensus of $126.5 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Herbalife board approves $250M share buyback over three years
- United Community Banks completes balance sheet repositioning, expands buyback
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
